Auxly Cannabis Group (XLY) Investor presentation summary
Event summary combining transcript, slides, and related documents.
Investor presentation summary
14 May, 2026Strategic positioning and market overview
Mission focuses on enhancing lives with trusted, quality cannabis products and aims for global leadership in the sector.
Operates as the #3 largest licensed producer in Canada, with coast-to-coast reach and presence in 10 provinces and 2 territories.
Canadian recreational cannabis market projected to reach CAD $7.4B by 2030, with increasing social acceptance and legal market penetration.
Canada serves as a global launchpad, leveraging regulatory leadership and export capabilities to access a US $102B global market by 2030.
Strategic partnership with Imperial Brands supports international expansion and infrastructure.
Brand leadership and operational excellence
Holds #1 positions in non-infused pre-rolls, all-in-one vapes, and flower categories nationally.
Eleven consecutive quarters of positive Adjusted EBITDA, reflecting operational efficiency and profitability.
State-of-the-art cultivation facility in Leamington, Ontario, produces over 100,000 kgs annually and is certified for export.
Advanced pre-roll automation and R&D partnerships ensure consistent, high-quality products at scale.
Charlottetown facility leads in vape innovation, with industry-low failure rates and robust product development.
Financial performance and sustainability
Q1 2026 net revenue reached $39.8M, with a 31% Adjusted EBITDA margin and $12.3M Adjusted EBITDA.
Trailing twelve months (TTM) net revenue at $159M, Adjusted EBITDA at $49M, and $44M cash flow from operations before working capital.
Year-over-year improvements in net revenue, gross margin, and Adjusted EBITDA, with sustainable cash flow generation.
Strong balance sheet with $42.7M net working capital and total debt at 0.9x TTM Adjusted EBITDA.
Fully diluted share count stands at 1.7B as of March 31, 2026.
Latest events from Auxly Cannabis Group
- Record Q1 revenue and EBITDA growth, strong cash flow, and new share repurchase program.XLY
Q1 202614 May 2026 - 2025 saw 24% revenue growth, 64% higher Adjusted EBITDA, and strong cash flow conversion.XLY
Q4 202527 Mar 2026 - Delivered 24% revenue growth in 2025 and leads Canadian cannabis with top brands and innovation.XLY
Investor presentation26 Mar 2026 - Q1 2025 saw 29% revenue growth, 48% gross margin, and a return to profitability, but liquidity risks persist.XLY
Q1 202511 Feb 2026 - Record Q2 2025 revenue, profit, and margins, with strong outlook and market leadership.XLY
Q2 202510 Feb 2026 - Net loss narrowed and debt fell, but going concern risk persists amid negative working capital.XLY
Q4 202410 Feb 2026 - Q3 2024 revenue, profit, and market share rose, but liquidity and debt risks persist.XLY
Q3 202410 Feb 2026 - Record Q2 revenue and margin gains, but going concern risks persist.XLY
Q2 202410 Feb 2026 - Record Q3 2025 results and innovation position the company for growth at home and abroad.XLY
Small Cap Growth Virtual Investor Conference 202513 Dec 2025